Axogen, Inc. (AXGN)

Axogen's stock price was impacted by the FDA extending the PDUFA goal date for its BLA for Avance® Nerve Graft, leading to a 9.04% drop in the stock price. There have also been reports of insider selling activity in October 2025, including sales by Director William P. Burke.

Axogen's product portfolio addresses a wide range of peripheral nerve repair applications, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. The diverse nature of these applications suggests a relatively consistent demand for Axogen's products rather than significant seasonality.

Axogen, Inc. is a medical technology company focused on surgical solutions for peripheral nerve regeneration and repair, operating in the Health Care Technology industry. Its core business involves developing and marketing innovative surgical solutions for peripheral nerve repair, utilizing products derived from human tissue processing and synthetic materials. Major products include Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, AxoGuard® Nerve Cap, Avive® Soft Tissue Membrane, AcroVal Neurosensory & Motor Testing System®, and AxoTouch® Two-Point Discriminator.

Axogen's products are available in the United States, Canada, the United Kingdom, Germany, Spain, South Korea, and several other international countries. The company has a presence in Germany through Axogen Germany GmbH.

Axogen's brand reputation has been subject to an investigation by Pomerantz LLP regarding potential securities fraud or unlawful business practices. The investigation was announced after the FDA extended the PDUFA goal date for Avance® Nerve Graft, which caused a significant drop in the company's stock price.

Axogen, Inc. is predominantly owned by institutional investors, who held approximately 84.7% of the company's shares as of Q4 2023. Major institutional owners include First Light Asset Management, LLC, BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, Balyasny Asset Management L.P., ArrowMark Colorado Holdings LLC, Soleus Capital Management, L.P., Wasatch Advisors LP, Assenagon Asset Management S.A., and State Street Corp. Insiders own shares in Axogen, Inc., with a reported value of US$13 million as of October 2025.